ID

35060

Description

Study ID: 104951 Clinical Study ID: 104951 Study Title: A Phase III, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0_ 1_ 6 month schedule in healthy female subjects aged 10 - 14 years. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00290277 https://clinicaltrials.gov/ct2/show/NCT00290277 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: HPV-16/18 L1/AS04 Vaccine Trade Name: N/A Study Indication: Infections, Papillomavirus This form contains information about non serious adverse events and should be filled in if any non-serious adverse event occured. This section must be checked for final assessment at the end of the study. Investigators had to follow-up subjects in the case of other non-serious AEs, until they completed the study or they were lost to follow-up.

Lien

https://clinicaltrials.gov/ct2/show/NCT00290277

Mots-clés

Versions (3)
  1. 13/02/2019 13/02/2019 -
  2. 13/02/2019 13/02/2019 -
  3. 13/02/2019 13/02/2019 -
Détendeur de droits

GlaxoSmithKline

Téléchargé le

13 février 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Evaluation of immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine in healthy females NCT00290277

Anglais

Non-Serious Adverse Events

1 Formulaires  
Administrative data
Description

Administrative data

Alias
UMLS CUI-1
C1320722
Subject number
Description

Subject number

Type de données

text

Alias
UMLS CUI [1]
C2348585
Protocol number
Description

Protocol number

Type de données

text

Alias
UMLS CUI [1,1]
C0008971
UMLS CUI [1,2]
C0600091
Visit number
Description

Visit number

Type de données

text

Alias
UMLS CUI [1]
C1549755
Date of visit
Description

Date of visit

Type de données

date

Alias
UMLS CUI [1]
C1320303
Number of non-serious adverse event
Description

This form has to be filled in once for each non-serious adverse event that occurred during the study period.

Type de données

integer

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0449788
Has any non-serious adverse events occurred during the study period, (as per protocol)?
Description

If YES, please complete the following items. A serious adverse event (SAE) was any untoward medical occurrence that: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization (NOTE: Complications that occurred during hospitalization were AEs. If a complication prolonged hospitalization or fulfilled any other serious criteria, the eventwas serious), resulted in disability/incapacity (NOTE: The term disability meant a substantial disruption of a personís ability to conductnormal life functions. This definition was not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting,diarrhoea, influenza, and accidental trauma (e.g. sprained ankle) which might have interfered or prevented everyday life functions but did not constitute a substantial disruptio), was a congenital anomaly/birth defect in the offspring of a study subject. Medical or scientific judgement had to be exercised in deciding whether reportingwas appropriate in other situations, such as important medical events that might nothave been immediately life-threatening or resulted in death or hospitalization butmight have jeopardized the subject or might have required medical or surgicalintervention to prevent one of the other outcomes listed in the above definition.These were also considered serious. Examples of such events were invasive ormalignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalization.

Type de données

boolean

Alias
UMLS CUI [1]
C1518404
Non-Serious Adverse Events
Description

Non-Serious Adverse Events

Alias
UMLS CUI-1
C1518404
Description of Non-SAE
Description

Description of Non-SAE

Type de données

text

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0678257
New onset of chronic diseases?
Description

Please check YES in case of new onset of chronic diseases.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0008679
UMLS CUI [1,2]
C0746890
Site of symptoms
Description

Site of symptoms

Type de données

text

Alias
UMLS CUI [1,1]
C2700396
UMLS CUI [1,2]
C0037088
Date started:
Description

Start date

Type de données

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C1518404
Start during immediate post-vaccination period (30 minutes)?
Description

Start during immediate post-vaccination period (30 minutes)

Type de données

boolean

Alias
UMLS CUI [1,1]
C0439659
UMLS CUI [1,2]
C1518404
UMLS CUI [1,3]
C0042196
UMLS CUI [1,4]
C0687676
UMLS CUI [1,5]
C0205253
Date stopped:
Description

End date

Type de données

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C1518404
Maximum intensity
Description

Mild: An adverse event which is easily tolerated by the subject, causing minimal discomfort and notinterfering with everyday activities. Moderate: An adverse event which is sufficiently discomforting to interfere with normal everyday activities. Severe: An adverse event which prevents normal, everyday activities. (In adults / adolescents, such an adverse event would, for example, prevent attendance at work / school and would necessitate the administration of corrective therapy).

Type de données

integer

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0518690
Is there a reasonable possibility that the AE may have been caused by the investigational product?
Description

Relationship to investigational products

Type de données

boolean

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C0013230
UMLS CUI [1,3]
C0439849
Outcome
Description

Outcome

Type de données

integer

Alias
UMLS CUI [1,1]
C1518404
UMLS CUI [1,2]
C1705586
Medically attended visit
Description

If YES, specify medically attended visit below.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0545082
UMLS CUI [1,2]
C1386497
UMLS CUI [1,3]
C1518404
Specify type of medically attended visit
Description

'Medical personnel' means a visit to or from medical personnel (medical doctor).

Type de données

text

Alias
UMLS CUI [1,1]
C0545082
UMLS CUI [1,2]
C1386497
UMLS CUI [1,3]
C1518404
UMLS CUI [1,4]
C0332307
Retour au début de la page

Similar models

Non-Serious Adverse Events

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Administrative data
C1320722 (UMLS CUI-1)
Subject number
Item
Subject number
text
C2348585 (UMLS CUI [1])
Protocol number
Item
Protocol number
text
C0008971 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
Item
Visit number
text
C1549755 (UMLS CUI [1])
Visit number
Code List
Visit number
CL Item
Visit 1 (Month 0) (Visit 1)
CL Item
Visit 2 (Month 1) (Visit 2)
CL Item
Visit 3 (Month 6) (Visit 3)
CL Item
Visit 4 (Month 7) (Visit 4)
Date of visit
Item
Date of visit
date
C1320303 (UMLS CUI [1])
Number of non-serious adverse event
Item
Number of non-serious adverse event
integer
C1518404 (UMLS CUI [1,1])
C0449788 (UMLS CUI [1,2])
Occurrence of non-serious adverse event
Item
Has any non-serious adverse events occurred during the study period, (as per protocol)?
boolean
C1518404 (UMLS CUI [1])
Item Group
Non-Serious Adverse Events
C1518404 (UMLS CUI-1)
Description of Non-SAE
Item
Description of Non-SAE
text
C1518404 (UMLS CUI [1,1])
C0678257 (UMLS CUI [1,2])
New onset of chronic diseases
Item
New onset of chronic diseases?
boolean
C0008679 (UMLS CUI [1,1])
C0746890 (UMLS CUI [1,2])
Item
Site of symptoms
text
C2700396 (UMLS CUI [1,1])
C0037088 (UMLS CUI [1,2])
Site of symptoms
Code List
Site of symptoms
CL Item
Administration site (a)
CL Item
Non-administration site (b)
Start date
Item
Date started:
date
C0808070 (UMLS CUI [1,1])
C1518404 (UMLS CUI [1,2])
Start during immediate post-vaccination period (30 minutes)
Item
Start during immediate post-vaccination period (30 minutes)?
boolean
C0439659 (UMLS CUI [1,1])
C1518404 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0687676 (UMLS CUI [1,4])
C0205253 (UMLS CUI [1,5])
End date
Item
Date stopped:
date
C0806020 (UMLS CUI [1,1])
C1518404 (UMLS CUI [1,2])
Item
Maximum intensity
integer
C1518404 (UMLS CUI [1,1])
C0518690 (UMLS CUI [1,2])
Maximum intensity
Code List
Maximum intensity
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
Relationship to investigational products
Item
Is there a reasonable possibility that the AE may have been caused by the investigational product?
boolean
C1518404 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
Item
Outcome
integer
C1518404 (UMLS CUI [1,1])
C1705586 (UMLS CUI [1,2])
Outcome
Code List
Outcome
CL Item
Recovered / resolved (1)
CL Item
Recovering / resolving (2)
CL Item
Not recovered / not resolved (3)
CL Item
Recovered with sequelae /resolved with sequelae (4)
Medically attended visit
Item
Medically attended visit
boolean
C0545082 (UMLS CUI [1,1])
C1386497 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
Item
Specify type of medically attended visit
text
C0545082 (UMLS CUI [1,1])
C1386497 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C0332307 (UMLS CUI [1,4])
Specify type of medically attended visit
Code List
Specify type of medically attended visit
CL Item
Hospitalization (HO)
CL Item
Emergency Room (ER)
CL Item
Medical Personnel (MD)
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial